Skip to main content
Equibles
PACB logo

PACB · Pacific Biosciences Of California, Inc. · Metrics

Track PACB — free

Use PACB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PACB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.14 +0.18 (+9.18%) At close · Oct 21
Russell 2000 member Rebalance outlook locked
Market Cap
$609.23M
Shares
310.83M
Volume · Oct 21 13.5M Avg daily vol (3M) 11.02M

PACB metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.14
Market cap
$609.23M

Price action

20 metrics
Price change (1W)
-4.4%
Price change (30D)
+44.1%
Price change (3M)
+40.0%
Price change (6M)
+13.3%
Price change (YTD)
+4.8%
Price change (1Y)
-1.0%
Trailing year
Price change (5Y)
-92.2%
52-week high
$2.87
52-week low
$1.11
Change from 52-week high
-31.7%
Change from 52-week low
+76.6%
Annualized volatility
93.4%
Annualized volatility (3M)
111.8%
Beta
2.3
RSI (14D)
50.9
Price vs SMA 50
+20.1%
Price vs SMA 200
+22.7%
Avg volume (3M)
10.92M
Relative volume
1.0
Average dollar volume
$20.59M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
310.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
6.1×
reciprocal yield 16.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
3.6×
reciprocal yield 27.8%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-23.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.2×
reciprocal yield 16.0%
EV / revenue historical average (5Y)
14.6×
reciprocal yield 6.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
36.4%
Operating margin
-83.5%
Trailing 12 months
Net margin
-82.5%
Gross profit (TTM)
$57.95M
Operating profit (TTM)
−$133.04M
Net income (TTM)
−$131.39M
Trailing 12 months
Diluted EPS (TTM)
$-0.41
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.52
Gross profit per diluted share (TTM)
$0.19
Operating profit per diluted share (TTM)
$-0.44
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.43
Operating cash flow per diluted share (TTM)
$-0.39
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.29
Stock compensation per diluted share (TTM)
$0.11
Book value per share
$0.02

Growth

11 metrics
Revenue growth YoY
-1.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$159.27M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.5%
Year over year · more shares
Revenue CAGR (3Y)
+7.6%
Revenue CAGR (5Y)
+15.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-17.5%
Debt / equity
—
Current ratio
4.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
4.0
Interest coverage
-18.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$407.46M
Latest balance sheet
Cash & equivalents
$61.00M
Total assets
$751.85M
Total debt
$644.33M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$118.05M
Capital expenditures (TTM)
$5.37M
R&D (TTM)
$88.36M
SG&A (TTM)
$129.70M
Stock compensation (TTM)
$34.29M
R&D / revenue
55.5%
Stock compensation / revenue
21.5%

Ownership (13F)

9 metrics
13F filers
223
13F filer change QoQ
-8
Institutional ownership
61.8%
Conviction holders (share of 13F filers)
0.4%
Crowding (high-turnover and private-fund holders)
22.0%
Private-fund adviser ownership
18.6%
Active holders' share change QoQ
-3.0%
Holder tenure
13.7
Price vs estimated holder cost
-63.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.6%

Short interest

3 metrics
Short interest
15.2%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$2.09M
Insider-sentiment score
52 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1299130 CUSIP 69404D108 13F (30d) 19 filings 19 filers Visit website Investor relations